ULTIMA trial: In the ultrasound accelerated thrombolysis of pulmonary embolism (ULTIMA) trial, 59 patients with intermediate-risk PE were randomized to either UFH (80 IU/KG) and the USAT regimen of 10 mg recombinant tPA over 15 hours per treated lung via the EkoSonic endovascular system or UFH alone (n=30 vs. 29, respectively). The gene discussed is PLAT; the disease is pulmonary embolism.